aap Implantate AG

aap Implantate AG: EBITDA guidance raised

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

aap informs about the actual status of the mandatory convertible bond 2023-2028

aap Implantate AG: Cash capital increase and intended non-cash capital increase

aap Implantate AG: Step-by-step restart of IT systems

aap Implantate AG: Possible cyber attack on aap

Progress in the MDR process – important MDR initial certification audit carried out

Very successful human clinical trial with the innovative antibacterial surface-treated implants receives approval for quick end of recruitment.

aap Implantate AG: annual financial statements 2023 characterized by the difficult economic environment and restructuring measures introduced, good operational progress

aap Implantate AG: Auditor will terminate audit and declare non-issuance of audit opinion due to audit impediments

Half-year financial statements close with balanced EBITDA, Trauma with positive EBITDA

aap Implantate AG: Korrektur: Bekanntmachung der Einberufung zur Hauptversammlung am 15.08.2024 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

Sales growth Q2/2024 +14 % and H1/2024 +10 % compared to previous year; positive development in all operating areas

aap Implantate AG: Bekanntmachung der Einberufung zur Hauptversammlung am 15.08.2024 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Amendment of the terms and conditions of the bond completed; Bondholders can convert bonds into shares

aap closes Q1 2024 with sales growth of 5.6% and positive developments at all operating levels and makes a strong start to Q2 2024